Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note published on Friday. The firm issued a sell rating on the stock.

A number of other research firms have also recently weighed in on SYRS. Piper Sandler reissued an “overweight” rating and issued a $5.00 target price (down previously from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.27 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.25 and a quick ratio of 2.25. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $8.17. The company has a fifty day moving average price of $1.68 and a 200 day moving average price of $3.39. The stock has a market cap of $7.28 million, a P/E ratio of -0.09 and a beta of 1.59.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the business posted ($1.35) EPS. Analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current year.

Insider Activity at Syros Pharmaceuticals

In other news, CFO Jason Haas purchased 45,344 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $1.68 per share, with a total value of $76,177.92. Following the completion of the purchase, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at $209,247.36. The trade was a 57.25 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired 130,707 shares of company stock valued at $206,491 over the last ninety days. 12.26% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals during the 3rd quarter valued at $34,000. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals during the 1st quarter worth about $64,000. Certuity LLC bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter valued at about $109,000. Acadian Asset Management LLC raised its position in shares of Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after acquiring an additional 163,234 shares during the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.